Get the Stockscreener App
9.63
0.84%
0.08
Leonabio Inc stock is traded at $9.63, with a volume of 20,444.
It is up +0.84% in the last 24 hours and down -15.15% over the past month.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
See More
Previous Close:
$9.55
Open:
$9.49
24h Volume:
20,444
Relative Volume:
0.34
Market Cap:
$90.46M
Revenue:
-
Net Income/Loss:
$-105.61M
P/E Ratio:
-0.4262
EPS:
-22.5948
Net Cash Flow:
$-45.73M
1W Performance:
+10.82%
1M Performance:
-15.15%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.20
$9.735
1-Week Range:
$8.24
$9.735
52-Week Range:
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Name
Leonabio Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
9.63 | 90.46M | 0 | -105.61M | -45.73M | -22.59 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-19-26 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Leonabio Inc Stock (LONA) Latest News
MSN Money - MSN
LONA Earnings History & Surprises | EPS & Revenue Results | LEONABIO INC (NASDAQ:LONA) - ChartMill
LONA LeonaBio reports sharply worse than expected Q4 2025 EPS, shares drop 3.36% on investor disappointment.Sector Underperform - Newser
Athira Pharma (LONA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $LONA - MarketBeat
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer - Yahoo Finance
LeonaBio (LONA) Showcases Lasofoxifene Research at AACR26 - GuruFocus
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data - The Manila Times
Independent Nonclinical Research on Lasofoxifene Presented - GlobeNewswire
LeonaBio (LONA) Stock: Is It Testing Levels (Overhead Buying) 2026-04-20Earnings Miss Stocks - Xã Thanh Hà
28,000-share stock option grant to LeonaBio (LONA) director - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to chief scientific officer - Stock Titan
28,000 stock options granted to LeonaBio (LONA) director Kosacz - Stock Titan
LeonaBio (LONA) director Grant Pickering receives 28,000 stock options - Stock Titan
Director Romano Kelly receives 28,000 LeonaBio (LONA) stock options at $9.54 - Stock Titan
LeonaBio (LONA) director receives options to buy 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) director awarded options on 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) grants CMO 350,000 options at $9.54 - Stock Titan
Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA) - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to general counsel - Stock Titan
LeonaBio (LONA) CFO awarded 300,000 stock options at $9.54 - Stock Titan
LeonaBio (LONA) CEO awarded 750,000 stock options at $9.54 strike - Stock Titan
LONA: LeonaBio, Inc.Comparison to Industry - Zacks Investment Research
Leonabio discovers new pannexin-1 inhibitors - BioWorld News
What is driving long-term growth of LeonaBio (LONA) Stock | Price at $11.68, Up 6.28%Fast Rising Picks - Newser
LONA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cantor Fitzgerald reiterates Overweight on LeonaBio stock By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Overweight on LeonaBio stock - Investing.com
Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook By Investing.com - Investing.com South Africa
Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook - Investing.com India
Mizuho Raises Price Target on LeonaBio to $16 From $10, Keeps Outperform Rating - marketscreener.com
[EFFECT] LeonaBio, Inc. SEC Filing - Stock Titan
Leonabio Warns of Major Financial and Operational Risks in Lasofoxifene Program Integration - TipRanks
LeonaBio (ATHA) clears resale of 5.5M warrant shares for Sermonix - Stock Titan
LeonaBio (NASDAQ: LONA) files resale registration for PIPE warrant holders - Stock Titan
LeonaBio (NASDAQ: ATHA) leans on breast cancer and ALS drugs - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
LeonaBio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
LeonaBio Reports 2025 Financial Results, Acquires Lasofoxifene License, and Advances Clinical Pipeline for Metastatic Breast Cancer and ALS 123 - Minichart
LeonaBio Updates Investors on 2025 Results and Strategy - TipRanks
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - Stock Titan
LeonaBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - Bitget
LeonaBio, Inc. announced that it has received $89.724073 million in funding - MarketScreener
LeonaBio (LONA) Stock Analysis Report | Financials & Insights - Benzinga Japan
LeonaBio, Inc. Adopts 2026 Equity Incentive Plan and Amends Certificate of Incorporation – SEC 8-K Filing March 2026 - Minichart
LeonaBio shareholders approve equity plan and increase in authorized shares - Investing.com India
Form 8K LeonaBio Inc For: 19 March - Investing.com
Leonabio Inc Stock (LONA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Leonabio Inc Stock (LONA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):